Evidence map›Paper›PMID 34944691›Full record

ArticleBiomedicines2021

α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease.

Kathrine Stokholm, Majken Borup Thomsen, Jenny-Ann Phan, Line K Møller, Cecilie Bay-Richter, Søren H Christiansen, David P D Woldbye, Marina Romero-Ramos, Anne M Landau

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. 2-Butoxytetrahydrofuran, Isolated fromACS chemical neuroscience · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kathrine StokholmDepartment of Nuclear Medicine & PET-Center, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Majken Borup ThomsenDepartment of Nuclear Medicine & PET-Center, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Jenny-Ann PhanDepartment of Nuclear Medicine & PET-Center, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Line K MøllerDepartment of Nuclear Medicine & PET-Center, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Cecilie Bay-RichterTranslational Neuropsychiatry Unit, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Søren H ChristiansenDepartment of Neuroscience, University of Copenhagen, 2200 N Copenhagen, Denmark.
David P D WoldbyeDepartment of Neuroscience, University of Copenhagen, 2200 N Copenhagen, Denmark.
Marina Romero-RamosNEURODIN, CNS Disease Modeling Group, Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
Anne M LandauDepartment of Nuclear Medicine & PET-Center, Institute of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.ORCID 0000-0002-7371-8713
Aarhus University · DKUniversity of Copenhagen · DK

Funding

Lundbeck Foundation 2013-16034Parkinsonforeningen to AML and MRR
6 · The paper itself

Abstract

Progressive degeneration of dopaminergic neurons, immune activation, and α-synuclein pathology characterize Parkinson's disease (PD). We previously reported that unilateral intranigral injection of recombinant adeno-associated viral (rAAV) vectors encoding wild-type human α-synuclein produced a rat model of early PD with dopamine terminal dysfunction. Here we tested the hypothesis that decreases in dopamine result in increased postsynaptic dopamine D2/D3 receptor expression, neuroinflammation, and reduced synaptic vesicle glycoprotein 2A (SV2A) density. Rats were injected with rAAV encoding α-synuclein or green fluorescent protein and subjected to non-pharmacological motor tests, before euthanization at 12 weeks post-injection. We performed: (1) in situ hybridization of nigral tyrosine hydroxylase mRNA, (2) HPLC of striatal dopamine content, and (3) autoradiography with [

Indexed as

adeno-associated viral vectorsautoradiographydopamineneuroinflammationParkinson’s diseasesynaptic vesicle glycoprotein 2Aα-synuclein

Identifiers

PMID34944691
PMCPMC8698691
OpenAlexW4200411622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.